Acute myeloid leukemia (AML) is a fast-growing cancer of the bone marrow, and a bone marrow transplant (more precisely, an allogeneic hematopoietic stem cell transplant) is the treatment most likely to cure it when chemotherapy alone is unlikely to keep it away. Not every patient needs a transplant. The decision depends on the leukemia’s genetic risk, how well it responds to the first round of chemotherapy, and whether the patient is fit enough to tolerate the procedure.
In this guide I walk through what AML is, how it is diagnosed and treated, and exactly where a transplant fits into that plan.
What Is Acute Myeloid Leukemia?
AML, also called acute myelogenous leukemia, starts in the myeloid line of blood-forming cells. These are the precursors that normally mature into neutrophils, monocytes, red cells, and platelets. In AML, a clone of immature cells called blasts multiplies rapidly and stops maturing, crowding out healthy production in the bone marrow.
The result is a marrow full of useless cells and a bloodstream short of working ones. The flood of abnormal white blood cells cannot fight infection, while red cells and platelets fall. AML is the most common acute leukemia in adults, and its risk rises with age.
Causes and Risk Factors
Most cases have no single identifiable cause. The disease arises from acquired genetic changes in marrow stem cells, not inherited ones in most patients. Recognized risk factors include:
- Older age
- Prior chemotherapy or radiation therapy for another cancer
- Exposure to benzene and some other industrial chemicals
- Smoking
- A previous marrow disorder such as myelodysplastic syndrome or a myeloproliferative neoplasm, or other hematologic disorders
- Certain inherited conditions, such as Down syndrome
Signs and Symptoms
Symptoms reflect the failure of normal blood production. Low red cells cause fatigue, breathlessness, and pallor. Low neutrophils bring fevers and repeated infections, and low platelets cause easy bruising, nosebleeds, bleeding gums, or tiny red spots on the skin called petechiae. Because AML progresses over days to weeks, these symptoms usually appear and worsen quickly.
How AML Is Diagnosed
A complete blood count is usually the first clue. It often shows anemia, low platelets, and a white count that may be high, normal, or low, with blasts visible on the blood smear. Reading stained slides is central here, which is why the role of color in leukemia diagnosis matters so much in how these abnormal cells are first recognized.
A bone marrow aspirate and biopsy confirms the diagnosis. Under the WHO classification, AML is generally diagnosed when blasts make up at least 20% of marrow or blood cells, although certain defining genetic abnormalities establish AML even at lower blast counts.
Why Genetic Testing Drives the Transplant Decision
The marrow sample is also tested with cytogenetics, FISH, and molecular panels such as next-generation sequencing. These results place the leukemia into a risk group, and that risk group is one of the main factors in deciding whether a transplant is recommended in first remission.
| Risk group | Typical genetic examples | Usual approach to transplant in first remission |
|---|---|---|
| Favorable | t(8;21), inv(16), mutated NPM1 without FLT3-ITD, certain CEBPA mutations | Often not needed; chemotherapy consolidation first, transplant kept for relapse |
| Intermediate | Normal karyotype without favorable mutations, some FLT3-ITD cases | Frequently considered, especially if a well-matched donor is available |
| Adverse | Complex karyotype, monosomal karyotype, TP53 mutations, certain chromosome 5 and 7 abnormalities | Generally recommended if the patient is fit |
Standard Treatment Before a Transplant
Treatment starts with induction chemotherapy, whose aim is complete remission: normal blood counts and fewer than 5% blasts in the marrow. For fit patients, the classic regimen is “7+3”, seven days of cytarabine with three days of an anthracycline such as daunorubicin. Targeted drugs, such as a FLT3 inhibitor for FLT3-mutated disease, may be added.
Remission is not cure, because leukemia cells too few to see often remain. The next phase, consolidation, aims to eliminate them. For favorable-risk disease that might be several cycles of higher-dose cytarabine. For higher-risk disease, consolidation very often means a transplant.
Older or less fit patients may receive lower-intensity treatment, such as a hypomethylating agent combined with venetoclax. Some of these patients can still go on to a transplant using gentler conditioning.
The Role of Bone Marrow Transplant in AML
In AML, the transplant used is almost always allogeneic, meaning the stem cells come from another person. It works in two ways. First, the conditioning chemotherapy (sometimes with radiation) destroys the patient’s marrow and much of the remaining leukemia. Second, the donor’s immune cells recognize any surviving leukemia cells as foreign and attack them, known as the graft-versus-leukemia effect. That immune effect is the main reason transplant can cure disease that chemotherapy cannot.
Who Is Offered a Transplant?
- Patients with intermediate- or adverse-risk AML in first complete remission
- Patients whose leukemia did not go into remission after induction
- Patients who relapse after earlier treatment, once a second remission is achieved where possible
- Patients whose measurable residual disease testing stays positive after chemotherapy
Finding a Donor
Donors are matched by HLA typing, the tissue markers the immune system uses to tell self from non-self. A brother or sister has a one-in-four chance of being a full match. When no sibling matches, doctors search volunteer registries for a matched unrelated donor, or consider a half-matched (haploidentical) family member or umbilical cord blood.
Conditioning Intensity
Myeloablative conditioning uses high doses to wipe out the marrow and is usually reserved for younger, fitter patients. Reduced-intensity conditioning relies more on the graft-versus-leukemia effect and less on chemotherapy dose, which has made transplant possible for many older adults and those with other health problems.
Risks and Recovery
A transplant is a major undertaking, and the benefit must outweigh the risk for each individual. The main complications are:
- Infections during the weeks before the new marrow engrafts, and for months afterward while immunity rebuilds
- Graft-versus-host disease (GVHD), in which donor immune cells attack the patient’s skin, gut, or liver
- Organ toxicity from conditioning, including mouth sores, liver injury, and lung problems
- Relapse of the leukemia despite transplant
- Longer-term effects such as infertility, cataracts, and hormonal changes
Donor cells usually engraft within about two to four weeks, when blood counts begin to recover. Most patients stay close to the transplant center for the first 100 days, with frequent checks for infection and GVHD. Full immune recovery commonly takes a year or more, and childhood vaccinations need to be repeated.
When to See a Doctor
Seek prompt medical review if you notice unexplained fatigue with bruising, bleeding gums, frequent fevers, or tiny red spots on the skin. These together call for a blood count the same day or next day. After a transplant, any fever, new rash, diarrhea, or yellowing of the eyes should be reported to the transplant team immediately.
Frequently Asked Questions
Does everyone with AML need a bone marrow transplant?
No. Many patients with favorable-risk AML are treated with chemotherapy alone and keep transplant in reserve in case of relapse. The recommendation depends on genetic risk, response to induction, residual disease testing, and overall fitness.
Can I use my own stem cells for AML?
An autologous transplant, using your own cells, is rarely used for AML. It lacks the graft-versus-leukemia effect, and the collected cells could contain leukemia. Allogeneic transplant from a donor is the standard.
Is there an age limit for transplant?
There is no fixed cut-off. Reduced-intensity conditioning has made transplant an option for many people in their 60s and 70s, and fitness and other health conditions matter more than age alone.
How is the transplant itself done?
After conditioning, the donor stem cells are given through a central line like a blood transfusion. The cells travel to the marrow on their own and begin producing new blood cells over the following weeks.
Key Takeaways
- AML is an aggressive marrow cancer that needs urgent diagnosis and treatment.
- Genetic testing of the marrow sorts AML into risk groups that guide the transplant decision.
- Allogeneic transplant cures many patients through the graft-versus-leukemia effect.
- Reduced-intensity conditioning has widened access to transplant for older adults.
- Transplant carries real risks, including infection and GVHD, so the choice is individual.
